| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 |
| Sales | 175,340 | 164,250 | 154,940 | 133,590 | 99,890 |
| Sales Growth | +6.75% | +6.01% | +15.98% | +33.74% | +254.22% |
| Net Income | -146,430 | -102,680 | -59,730 | -47,900 | 117,240 |
| Net Income Growth | -42.61% | -71.91% | -24.70% | -140.86% | +205.68% |
Retrophin Inc (RTRX)
24.25 -0.11 (-0.45%) 11/19/20 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
for Wed, Nov 18th, 2020
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal', Cholbam, and Thiola', and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.